Author(s): Viani Anggi, Andi Atirah Masyita

Email(s): viani.anggi@gmail.com

DOI: 10.52711/0974-360X.2022.00105   

Address: Viani Anggi1, Andi Atirah Masyita2
1College of Pharmaceutical Sciences Pelita Mas Palu, Central Sulawesi 94111, Indonesia.
2Department of Pharmacy, Faculty of Pharmaceutical, Tadulako University, Central Sulawesi 94111, Indonesia.
*Corresponding Author

Published In:   Volume - 15,      Issue - 2,     Year - 2022


ABSTRACT:
Introduction: Breast Cancer is one of the diseases, which the ranks are first on death to the female sex. breast cancer characterized by the growth of uncontrolled breast cancer cells and ability to attack the local organs like as metastases and spread in breast tisue including ducts and lobules. Alternative treatment for breast cancer is combined with chemotherapy and chemopreventive non-toxic agent to breast cancer cells Objective: The research of the study is to evaluate potential synergism the in-vitro cytotoxicity combination effects from a combination of the Abelmoschus manihot (L.) Medik of (N-Hexane) extracts and Doxorubicin in breast cancer 4T1 cells line. Methods: The study is suggested combination effects of Abelmoschus manihot (L.) Medik of (N-Hexane) extracts and Doxorubicin in breast cancer 4T1 cells line, where carried out against with use table of concentration from Abelmoschus manihot (L.) Medik extracts (N-Hexane) and Doxorubicin as a Chemotherapy agent. Results: The potential of Abelmoschus manihot (L.) Medik of n-hexane extract can be combination with cytotoxicity agent Doxorubicin on 4T1 breast cancer cells line with concentration of N-Hexane extract 185,0 µg/ml and the concentration of Doxorubicin 25 nM, where the Combination Index (CI) values 0,89 < 1 shows synergist combination. Conclusion: The Abelmoschus manihot (L.) Medik of n-hexane extract is synergism with cytotoxic agent Doxorubicin in 4T1 breast cancer cells line.


Cite this article:
Viani Anggi, Andi Atirah Masyita. Combination Effects of Abelmoschus manihot (L.) Medik of N-Hexane extracts and Doxorubicin in Breast cancer 4T1 Cells Line. Research Journal of Pharmacy and Technology. 2022; 15(2):639-2. doi: 10.52711/0974-360X.2022.00105

Cite(Electronic):
Viani Anggi, Andi Atirah Masyita. Combination Effects of Abelmoschus manihot (L.) Medik of N-Hexane extracts and Doxorubicin in Breast cancer 4T1 Cells Line. Research Journal of Pharmacy and Technology. 2022; 15(2):639-2. doi: 10.52711/0974-360X.2022.00105   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-2-25


REFERENCES:
1.    Ataollahi MR, Sharifi J, Paknahad MR, Paknahad A. Breast cancer and associated factors: a review. J Med Life. 2015;8(Spec Iss 4):6-11. http://www.ncbi.nlm.nih.gov/pubmed/28316699%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5319297
2.    Labrèche F, Goldberg MS, Hashim D, Weiderpass E. Breast cancer. Occup Cancers. Published online 2020:417-438. doi:10.1007/978-3-030-30766-0_24
3.    Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biol. 2020; 29 (November 2019):101394. doi:10.1016/j.redox.2019.101394
4.    Jiyoung L, Jinhee P, Jinsung C, Gyouchul J, Changhwan Y. The effect of CIK-cell therapy in combination with anticancer agents in patients with inoperable pancreato-biliary cancer. Integr Cancer Sci Ther. 2020;7(2):1-3. doi:10.15761/icst.1000336
5.    Anggi V, Adikusuma W. Total antioxidant and in-vitro cytotoxic of abelmoschus manihot (L.) medik from palu of central sulawesi and doxorubicin on 4t1 cells line and vero cells. Res J Pharm Technol. 2019;12(11):5472-5476. doi:10.5958/0974-360X.2019.00949.1
6.    Flobak Å, Niederdorfer B, Nakstad VT, Thommesen L, Klinkenberg G, Lægreid A. A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines. Sci data. 2019;6(1):237. doi:10.1038/s41597-019-0255-7
7.    Haryanti S, Pramono S, Murwanti R, Meiyanto E. The Synergistic Effect of Doxorubicin and Ethanolic Extracts of Caesalpinia sappan L. Wood and Ficus septica Burm. f. Leaves on Viability, Cell Cycle Progression, and Apoptosis Induction of MCF­7 Cells. Indones J Biotechnol. 2017;21(1):29. doi:10.22146/ijbiotech.26105
8.    Nn A. A Review on the Extraction Methods Use in Medicinal Plants, Principle, Strength and Limitation. Med Aromat Plants. 2015;04(03):3-8. doi:10.4172/2167-0412.1000196
9.    Tsakalozou E, Eckman AM, Bae Y. Combination effects of docetaxel and doxorubicin in hormone-refractory prostate cancer cells. Biochem Res Int. 2012;2012. doi:10.1155/2012/832059
10.    Hadi I, Jenie RI, Meiyanto E. Pentagamavunon-0 (PGV-0) Enhance Cytotoxic Effect of Doxorubicin through Increasing of Apoptosis, Senescence and ROS Level on Triple Negative Breast Cancer 4T1. Indones J Cancer Chemoprevention. 2020;11(1):7. doi:10.14499/indonesianjcanchemoprev11iss1pp7-15
11.    Pearce J V., Farrar JS, Lownik JC, et al. E0771 and 4T1 murine breast cancer cells and interleukin 6 alter gene expression patterns but do not induce browning in cultured white adipocytes. Biochem Biophys Reports. 2019;18:1-10. doi:10.1016/j.bbrep.2019.100624
12.    A BO, Cell L, Lines C, Plant M. In - vitro Cytotoxic Activity of Indianthus virgatus (Roxb.) Lines. Pharmacogn J. 2018;10(6):1216-1220.
13.    Huang, L., Jiang, Y. and Chen Y. Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway. Sci Rep. 2017;7:40752.
14.    Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 2010;70(2):440-446. doi:10.1158/0008-5472.CAN-09-1947
15.    Xiong Y, Ye T, Wang M, et al. A novel cinnamide YLT26 induces breast cancer cells apoptosis via ROS-mitochondrial apoptotic pathway in vitro and inhibits lung metastasis in vivo. Cell Physiol Biochem. 2014;34(6):1863-1876. doi:10.1159/000366385

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available